NVO News

Recent headlines mentioning NVO, newest first.

NVO bullish

BCMA Targeted Therapies Competitive Landscape Analysis: 100+ Pipeline Therapies Driving Innovation in Therapeutics Segment | DelveInsight

manilatimes.net·Nov 12, 2026·The BCMA targeted therapies competitive landscape report delivers important insights into approved as well as ongoing research on 100+ pipeline BCMA targeted th...
NVO bullish

Lilly Stock Rises as China Clears Its Weight-Loss Pill

gurufocus.com·Nov 12, 2026·Eli Lilly and Co. LLY rose 2.97% in premarket after China's medicine regulator approved its weight-loss pill orforglipron. The approval gives Lilly an edge over...
NVO bullish

GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight

manilatimes.net·Nov 11, 2026·The GLP-1 RAs & incretin-based therapies competitive landscape report offers key insights into approved and ongoing research on 200+ pipeline GLP-1 RAs & incret...
NVO bullish

Type 2 Diabetes Clinical Trial and Competitive Landscape Analysis: 200+ Key Companies Shaping the Future of Type 2 Diabetes Therapeutics Space | DelveInsight

manilatimes.net·Nov 10, 2026·The type 2 diabetes competitive landscape report delivers important insights into approved as well as ongoing research on 200+ pipeline type 2 diabetes drugs, c...
NVO neutral

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

zacks.com·Nov 10, 2026·We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...
NVO neutral

Tech and Earnings in Focus: Market Navigates Corporate Results Amid Economic Uncertainty

thestockmarketwatch.com·Nov 4, 2026·This update was written automatically with AI from market data and news wire reports, and published without review by a person. Market Overview and Premarket A...
NVO bullish

Bullish Momentum Sweeps Wall Street as Major Indexes Surge and Earnings Season Hits High Gear

thestockmarketwatch.com·Nov 4, 2026·This update was written automatically with AI from market data and news wire reports, and published without review by a person. Market Performance and Index Tr...
NVO bullish

Novo Nordisk Q3 Adj. Operating Profit Increases, Obesity Sales Up 22%; Raises 2026 Outlook

rttnews.com·Nov 4, 2026·Novo Nordisk A/S (NVO,NOVOB.CO,NOV.DE) reported third quarter net profit of 16.74 billion Danish kroner, a decline of 16% year-over-year. Earnings per share/ AD...
NVO bullish

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

manilatimes.net·Oct 22, 2026·The Alzheimer's disease competitive landscape report delivers important insights into approved as well as ongoing research on 240+ pipeline Alzheimer's disease ...
NVO bearish

Novo's New Obesity Drug Just Hit 25% Weight Loss in Women

gurufocus.com·Oct 21, 2026·Novo Nordisk A/S (NVO, Financials) is out with fresh phase 3 results on its investigational CagriSema obesity medicine, which showed an average decrease of 25% ...
NVO bullish

Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight

manilatimes.net·Oct 21, 2026·The metabolic dysfunction-associated steatohepatitis competitive landscape report delivers important insights into approved as well as ongoing research on 200+ ...
NVO neutral

Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?

zacks.com·Oct 19, 2026·We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...
NVO bullish

Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground

insidermonkey.com·Oct 16, 2026·Novo Nordisk S/A (NYSE:NVO)’s investment story has changed dramatically. The stock has declined by over 25% since the start of 2026. The selloff has changed t...
NVO bullish

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight

manilatimes.net·Oct 15, 2026·The obesity competitive landscape report delivers important insights into approved as well as ongoing research on 200+ pipeline obesity drugs, clinical strategi...
NVO neutral

Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response

insidermonkey.com·Oct 8, 2026·During the October 1 lightning round of Mad Money, a caller said they owned both Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY). After contras...
NVO neutral

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

zacks.com·Oct 6, 2026·We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...
NVO neutral

Novo Looks Beyond GLP-1s as Competition Intensifies

insidermonkey.com·Oct 5, 2026·In the past, Novo Nordisk A/S (NYSE:NVO) has been a dominant player in diabetes and obesity treatments, with Ozempic and Wegovy driving a significant portion of...
NVO bullish

Can Novo Nordisk (NVO) Turn Monthly Dosing into Growth?

insidermonkey.com·Sep 29, 2026·It was reported on September 25 that Novo Nordisk A/S (NYSE:NVO) has entered into an exclusive global license and collaboration agreement with Swedish drug deli...
NVO bullish

Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?

insidermonkey.com·Sep 28, 2026·Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diab...
NVO neutral

Can Novo Nordisk (NVO) Find a Second Act Before its First One Fades?

insidermonkey.com·Sep 28, 2026·A stock that has lost more than 70% of its value from the peak tends to invite hard questions, and Novo Nordisk A/S (NYSE:NVO) is now facing them from its own i...
NVO neutral

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

zacks.com·Sep 25, 2026·We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...
NVO neutral

Ozempic & Wegovy maker Novo looks to expand India portfolio through investments in new technologies

thehindubusinessline.com·Sep 24, 2026·Danish healthcare company Novo Nordisk is open to invest in technologies that innovate, even personalise treatment for diabetes and obesity, said a top company ...
NVO bullish

Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine (NYSE:NVO)

seekingalpha.com·Sep 24, 2026·So, following my May article , "Wall Street Underestimates Novo Nordisk's GLP-1 Comeback," Novo Nordisk A/S ( NVO ) stock, native ticker NOVO-B.CO, rose by as m...
NVO neutral

Novo CEO signals M&A opportunities to strengthen drug pipeline

cnbc.com·Sep 22, 2026·Mike Doustdar, chief executive officer of Novo Nordisk A/S, during an interview in New York, US, on Wednesday, Feb. 11, 2026. Novo CEO Mike Doustdar told CNBC ...
NVO bearish

Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers

gurufocus.com·Sep 21, 2026·Novo Nordisk A/S NVO shares fell 5.96% in Copenhagen trading, as the Danish drugmaker used its London Capital Markets Day to lay out 2030 strategic ambitions, t...
NVO neutral

Tech and Crypto Lead Markets Higher as Trading Commences for the Week

thestockmarketwatch.com·Sep 21, 2026·U.S. equity markets opened the week of Monday, September 21st, 2026, with a decisive move to the upside, fueled by a resurgence in technology sentiment and sign...
NVO bearish

The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?

insidermonkey.com·Sep 20, 2026·Morgan Stanley has cut Novo Nordisk A/S (NYSE:NVO) to Underweight on September 11, 2026. Semaglutide, the underlying molecule for Wegovy and Ozempic, generates ...
NVO neutral

Novo CEO Says Drugmaker Needs to “Rethink” its Obesity Strategy

finance.yahoo.com·Sep 18, 2026·Novo Nordisk A/S (NYSE:NVO) decision to use "Novo" as its day-to-day name is part of a broader attempt by CEO Mike Doustdar to reset the company's culture and s...
NVO neutral

Novo Nordisk (NVO) Pulls the Plug on Two More Heart Drug Trials

insidermonkey.com·Sep 17, 2026·On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, furth...
NVO bearish

Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds

finance.yahoo.com·Sep 17, 2026·On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, tho...
NVO bearish

Novo Nordisk Stock Falls After Major Rebrand

gurufocus.com·Sep 15, 2026·Novo Nordisk NVO shares fell 2% on Tuesday even after the drugmaker introduced a new brand identity and updated its corporate culture, as an analyst said the ch...
NVO neutral

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

manilatimes.net·Sep 14, 2026·- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendi...
NVO bullish

Novo Nordisk Expands Wegovy’s Reach with China MASH Approval

insidermonkey.com·Sep 14, 2026·Novo Nordisk A/S (NYSE:NVO) has received approval in China for Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-...
NVO neutral

Novo Nordisk A/S - share repurchase programme

manilatimes.net·Sep 14, 2026·Bagsværd, Denmark, 14 September 2026 - On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/201...
NVO neutral

Novo Nordisk rebrands as Novo to compete in obesity market

finance.yahoo.com·Sep 14, 2026·Novo Nordisk announced Monday that it is rebranding under the single name "Novo" and introducing a new corporate culture framework as it works to close a wideni...
NVO neutral

Can Oral Wegovy Help Novo Nordisk Capture China’s $4.46 Billion GLP-1 Opportunity?

insidermonkey.com·Sep 9, 2026·Novo Nordisk A/S (NYSE:NVO) has moved one step closer to bringing its oral Wegovy treatment to China after the country’s drug regulator accepted the company?...
NVO bullish

Wegovy’s Latest Trial Gives Novo Nordisk (NVO) Another Potential Growth Catalyst

insidermonkey.com·Sep 7, 2026·Novo Nordisk A/S (NYSE:NVO) has delivered encouraging late-stage data for Wegovy in younger children, with its STEP Young trial showing that 40.4% of children a...
NVO neutral

Futures Drop As Iran Hostilities Send Brent To 6 Week High Above $97

zerohedge.com·Sep 7, 2026·US stock futures slipped in cautious, low volume trading as the latest Middle East escalation pushed oil prices higher, lifting bond yields in Europe and Asia. ...
NVO neutral

Novo Nordisk A/S - share repurchase programme

manilatimes.net·Sep 7, 2026·Bagsværd, Denmark, 07 September 2026 - On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/201...
NVO bearish

SA’s R3bn weight-loss drug boom: treatment, opportunity or a new divide?

biznews.com·Sep 4, 2026·Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark Photographer: Carsten Snejbjerg/Bloomberg Health SA’s R3bn weight...